Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Dec. 31, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that...

from PR Newswire: https://prn.to/2AmKYh0